BBA
CLRB icon

Baader Bank Aktiengesellschaft’s Cellectar Biosciences CLRB Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,765
Closed -$43.1K – 454
2025
Q1 		$43.1K Buy
+5,765
New +$52.2K ﹤0.01% 382

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Baader Bank Aktiengesellschaft's CLRB Position: Q2 2025 in Review

Baader Bank Aktiengesellschaft sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 5,765 shares — an estimated $43.1K sold.

Baader Bank Aktiengesellschaft first reported a position in CLRB in Q1 2025 and held it in 1 quarter. The position peaked at $43.1K in Q1 2025. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • Baader Bank Aktiengesellschaft reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 5,765 Cellectar Biosciences shares in Q2 2025, an estimated $43.1K.
  • Baader Bank Aktiengesellschaft first reported a position in Cellectar Biosciences in Q1 2025 and held it in 1 quarter.
  • Baader Bank Aktiengesellschaft's Cellectar Biosciences position peaked at $43.1K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2025, filed 10 Jul 2025.